Data Foundry

Drug recalls 2023

ROPivacaine HCl 0 — Class II drug recall D-0147-2024

Completed recall by STAQ Pharma, Inc., reported 2023-12-13, distributed nationwide. STAQ Pharma Inc. received consumer complaints related to leaking bags and other potential bag concerns. Upon i

Recall numberD-0147-2024
Product typeDrug
ClassificationClass II
StatusCompleted
Voluntary or mandatedVoluntary
Recalling firmSTAQ Pharma, Inc., Denver, CO, United States
Recall initiated2023-11-29
Classified2023-12-07
Reported by FDA2023-12-13
DistributedNationwide (US)
Quantity2,616 bags
Reason classespackaging
NDC73177-0109-26
Lot numbers23109472A, 23109473A, 23109474A, 23109491A, 23109492A, 23109501A, 23109520A, 23109521A, 23109522A
Expiration dates2024-03-10, 2024-03-11, 2024-03-13, 2024-03-16, 2024-03-19, 2024-03-25, 2024-04-03, 2024-04-10, 2024-04-13

Product

ROPivacaine HCl 0.2% PF in Sodium Chloride 1,000 mg/500 mL (2 mg per mL) Injection, 500 mL bags, Rx only, STAQ Pharma Inc. 14135 E 42nd Ave, Unit 50, Denver, Colorado 80239, NDC 73177-0109-26,

Reason for recall

STAQ Pharma Inc. received consumer complaints related to leaking bags and other potential bag concerns. Upon investigation, they determine the source of the issue was with the bag manufacturer who released bags Lot # 134142-001A which had failed internal QC tests for leaks.

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0147-2024. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.